Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 14, 2026, addresses a change in Baxter International Inc.'s reportable segments effective for the quarterly period ended June 30, 2026. The change aligns with a new operating model to better align decision-making, cost structure, and execution.
Key Financial Metrics and Segment Changes
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. Instead, it details a structural reorganization of financial reporting:
- Segment Restructuring: The Company reduced its reportable segments from three to two:
- Medical Products & Therapies (MPT): Now includes the former Pharmaceuticals segment (reclassified into the Infusion Therapies & Platforms division) and certain manufacturing facility sales previously reported in "Other."
- Healthcare Systems & Technologies (HST): Remains unchanged.
- Cost Allocation: Certain shared corporate expenses will now remain unallocated rather than being fully allocated to segments.
- Impact on Consolidated Statements: These changes do not impact previously issued consolidated financial statements, net income, earnings per share, total assets, or stockholder's equity.
Material Changes Versus Prior Period
The primary material change is the recasting of historical segment and product category financial information for the quarterly period ended March 31, 2026, and the years ended December 31, 2025 and 2024. This recasting is provided in Exhibit 99.1 to ensure comparability with the new reporting structure. The filing explicitly states this is not a restatement of previously issued financial statements.
Guidance, Outlook, and Non-GAAP Measures
The filing introduces specific non-GAAP financial measures to aid in performance analysis:
- Operational Sales Growth: Excludes the impact of the Kidney Care MSA (not reflected in reportable segments), reflects the exit of IV solutions in China, and is calculated at constant currency rates.
- Organic Sales Growth: Excludes the Kidney Care MSA, impacts of business acquisitions or divestitures, and is calculated at constant currency rates.
- Management Commentary: Management believes these measures provide a more complete understanding of net sales growth by removing the effects of foreign exchange fluctuations and specific strategic exits or agreements.
Investor Verification Checklist
- Review Exhibit 99.1 for the unaudited recast segment financial information for Q1 2026 and full years 2024-2025.
- Verify the specific financial impact of the Pharmaceuticals segment reclassification into the MPT segment.
- Confirm the treatment of the Kidney Care MSA sales in the "Other" category versus reportable segments.
- Compare the new unallocated corporate expense approach against prior period fully allocated costs to assess segment margin changes.
- Reconcile the non-GAAP operational and organic sales growth metrics with GAAP net sales figures in the referenced 10-Q and 10-K filings.